Vaccine Being Tested To Prevent Dementia In People With Down Syndrome

BOSTON (CBS) – Local researchers are testing an experimental vaccine that may not only prevent Alzheimer’s disease in people with Down syndrome, but in those without Down syndrome as well. People with Down syndrome are at high risk of developing Alzheimer’s-like dementia at a very young age. Michael Clayburgh, 29, has Down syndrome, but that doesn’t hold him back. “Michael has three jobs,” says Nancy Novelline Clayburgh, Michael’s mom.  “He works at Target, McDonald’s and Dunkin Donuts.” Dr. Brian Skotko and Michael Clayburgh (WBZ-TV) He’s also quite the Special Olympics athlete, but perhaps Michael’s greatest contribution will be a scientific one. “He could be a major factor in finding the cure to Alzheimer’s,” explains Nancy. People with Down syndrome have an extra copy of chromosome 21.  One of the genes on that chromosome can lead to plaque build-up in the brain. “That goop in the brain when it starts to come together can really disrupt neuronal function and lead to the dementia that’s associated with Alzheimer’s,” explains Dr. Brian Skotko, director of the Down Syndrome Program at Massachusetts General Hospital. He says up to 50 percent of people with Down syndrome will develop dementia by age 50.  He worries about his 38-year-old sister, Kristin, who also has Down syndrome. Dr. Brian Skotko and his sister Kristin (WBZ-TV) “Because o...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Boston News Health Healthwatch Seen On WBZ-TV Syndicated Local Alzheimer's Disease Dementia Down Syndrome Dr. Mallika Marshall Source Type: news

Related Links:

Carla M. Startin1,2,3*, Bryony Lowe2,3, Sarah Hamburg1,2,3, Rosalyn Hithersay1,2,3, Andre Strydom1,2,3 and LonDownS Consortium 1Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom2Division of Psychiatry, University College London, London, United Kingdom3LonDownS Consortium, London, United Kingdom Down syndrome (DS) is associated with intellectual disability and an ultra-high risk of developing dementia. Informant ratings are invaluable to assess abilities and related changes in adults with DS, particularl...
Source: Frontiers in Psychiatry - Category: Psychiatry Source Type: research
Conclusion
Source: blog.bioethics.net - Category: Medical Ethics Authors: Tags: Health Care syndicated Source Type: blogs
er MQ Abstract There is evidence that frontal-subcortical circuits play an important role in the initial presentation of dementia in Down syndrome (DS), including changes in behavior, a decline in working memory and executive dysfunction. We evaluated 92 individuals with DS (≥30 years of age), divided into 3 groups by diagnosis-stable cognition, prodromal dementia, and Alzheimer's disease. Each individual was evaluated with an executive protocol developed for people with intellectual disabilities and was rated for behaviors related to frontal lobe dysfunction (disinhibition, executive dysfunction, and apat...
Source: Neurobiology of Aging - Category: Geriatrics Authors: Tags: Neurobiol Aging Source Type: research
A comparison of the spatial patterns of β-amyloid (Aβ) deposits in five neurodegenerative disorders. Folia Neuropathol. 2018;56(4):284-292 Authors: A Armstrong R Abstract Alzheimer's disease neuropathologic change (ADNC) in the form of -amyloid (A) deposits is important not only in the pathogenesis of Alzheimer's disease (AD) and Down's syndrome (DS) but also as a 'co-pathology' in disorders such as dementia with Lewy bodies (DLB), corticobasal degeneration (CBD), and chronic traumatic encephalopathy (CTE). To compare cortical and hippocampal degeneration in different disorder...
Source: Folia Neuropathologica - Category: Neurology Tags: Folia Neuropathol Source Type: research
Dementia in Down syndrome: unique insights for Alzheimer disease researchDementia in Down syndrome: unique insights for Alzheimer disease research, Published online: 07 February 2019; doi:10.1038/s41582-018-0132-6Alzheimer disease (AD) pathology is found in almost all adults with Down syndrome (DS), primarily owing to overexpression of APP, present on chromosome 21. Here, Lott and Head examine the commonalities and disparities between DS and AD and highlight findings in DS that can inform research into AD in the general population.
Source: Nature Reviews Neurology - Category: Neurology Authors: Source Type: research
Abstract Down syndrome (DS) is characterised by abnormal cognitive and motor development, and later in life by progressive Alzheimer's disease (AD)-like dementia, neuropathology, declining motor function and shorter life expectancy. It is caused by trisomy of chromosome 21 (Hsa21), but how individual Hsa21 genes contribute to various aspects of the disorder is incompletely understood. Previous work has demonstrated a role for triplication of the Hsa21 gene DYRK1A in cognitive and motor deficits, as well as in altered neurogenesis and neurofibrillary degeneration in the DS brain, but its contribution to other DS ph...
Source: Neurobiology of Disease - Category: Neurology Authors: Tags: Neurobiol Dis Source Type: research
In the Editorial titled “Prevalence and Severity of Alzheimer Disease in Individuals With Down Syndrome,” published online November 19, 2018, a typographical error was corrected in the sentence in the third paragraph that includes the phrase “late-onset epilepsy increased mortality risk in individuals with DS and dem entia by 10-fold.” The phrase “in individuals with DS and dementia” was changed to “in individuals with DS without dementia.”
Source: JAMA Neurology - Category: Neurology Source Type: research
(Center for Genomic Regulation) European scientists have launched a research program, which aims to identify common causes of dementia in Alzheimer's Disease, Parkinson's Disease and Down Syndrome. The project brings together basic and clinical expertise of internationally recognized groups with complementary core competencies from clinical trials to neurobiology.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
DISCUSSION: Our findings address uncertainties around the development of randomized controlled trials to delay cognitive decline in DS. Such trials are essential to reduce the high burden of dementia in people with DS and could serve as proof-of-principle trials for some drug targets. PMID: 30503169 [PubMed - as supplied by publisher]
Source: The Journal of Alzheimers Association - Category: Psychiatry Tags: Alzheimers Dement Source Type: research
DiscussionOur findings address uncertainties around the development of randomized controlled trials to delay cognitive decline in DS. Such trials are essential to reduce the high burden of dementia in people with DS and could serve as proof-of-principle trials for some drug targets.
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - Category: Geriatrics Source Type: research
More News: Alzheimer's | Brain | Clinical Trials | Dementia | Down's Syndrome | Genetics | Health | Hospitals | Jobs | Neurology | Neuroscience | Sports Medicine | Study | Vaccines